ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Amurins
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • Exebacase
    • CF-370
    • Gram-negative Lysins
    • Amurins
  • Investors & Media
    • Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Analyst Coverage
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Press Releases

Investors & Media

  • Home
  • Investors & Media
  • News / Events
  • Press Releases
Investors & Media

Investors & Media

  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • Events
    • Email Alerts
  • Presentations
  • Company Information
  • Financial Information
  • Analyst Coverage
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update

November 13, 2020

ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients

October 26, 2020

ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conference

September 9, 2020

ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation

August 25, 2020

ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update

August 14, 2020

ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development

July 20, 2020

Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation

June 17, 2020

ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors

June 15, 2020

ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.

May 26, 2020

ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants

May 21, 2020

RSS
  • 1
  • 2
  • 3
  • Next »
© 2023 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Expanded Access Policy Disclaimer Site Map
LinkedIn Twitter